Lifitegrast | B1917

Lifitegrast is a LFA-1 (lymphocyte function-associated antigen-1) antagonist intended for the treatment of vascular complications of the eye. Lifitegrast is a novel T-cell integrin antagonist that is designed to mimic the binding epitope of ICAM-1. It serves as a molecular decoy to block the binding of LFA-1/ICAM-1 and inhibits the downstream inflammatory process

Lifitegrast is a LFA-1 (lymphocyte function-associated antigen-1) antagonist intended for the treatment of vascular complications of the eye. Lifitegrast is a novel T-cell integrin antagonist that is designed to mimic the binding epitope of ICAM-1. It serves as a molecular decoy to block the binding of LFA-1/ICAM-1 and inhibits the downstream inflammatory process

B1917 | Lifitegrast DataSheet

Alternate Name/Synonyms: (S)-2-(2-(benzofuran-6-carbonyl)-5,7-dichloro-1,2,3,4-tetrahydroisoquinoline-6-carboxamido)-3-(3-(methylsulfonyl)phenyl)propanoic acid; SAR-1118; SAR 1118; SAR1118; Lifitegrast, Xiidra.

Appearance: White to off-white solid

Formulation: N/A

CAS Number: 1025967-78-5

Structure Available?: Yes

Peptide sequence: N/A

Salt Form: No

Molecular Formula: C₂₉H₂₄Cl₂N₂O₇S

Molecular Weight: 615.48

Cell-Permeable?: Yes

Purity: ≥98% by HPLC

Solubilities: DMSO (~ 30 mg/ml)

Handling: Protect from air and light

Country of Origin: USA

Tag Line: A LFA-1 (lymphocyte function-associated antigen-1) antagonist

MDL Number: N/A

PubChem CID: 11965427

SMILES: CS(=O)(=O)C1=CC=CC(=C1)CC(C(=O)O)NC(=O)C2=C(C=C3CN(CCC3=C2Cl)C(=O)C4=CC5=C(C=C4)C=CO5)Cl

InChi: InChI=1S/C29H24Cl2N2O7S/c1-41(38,39)20-4-2-3-16(11-20)12-23(29(36)37)32-27(34)25-22(30)13-19-15-33(9-7-21(19)26(25)31)28(35)18-6-5-17-8-10-40-24(17)14-18/h2-6,8,10-11,13-14,23H,7,9,12,15H2,1H3,(H,32,34)(H,36,37)/t23-/m0/s1

InChi Key: JFOZKMSJYSPYLN-QHCPKHFHSA-N